FMC three-lens brief
Evidence-based stock research on FMC. Three independent lenses — Quality, Momentum, Context — examine live data from SEC filings, the Federal Reserve, and market feeds. Every claim traces to its primary source.
Analyst mean target $17.76 — 19% above current (17 analysts). · Trading at 8% of its 52-week range — deep in the lower band.
- Trading at 8% of its 52-week range — deep in the lower band.
- Currently unprofitable on a trailing basis — no P/E multiple available.
- Analyst mean target $17.76 — 19% above current (17 analysts).
- Debt-to-equity of 245.1 — balance-sheet-heavy.
FMC closed at $14.89 (+0.47%) as of 2026-05-04. Market cap: $1.86B. Positives: analyst mean target $17.76 — 19% above current (17 analysts).. Concerns: trading at 8% of its 52-week range — deep in the lower band.; currently unprofitable on a trailing basis — no P/E multiple available.. Last quarter: Revenue $758.60M, net income -$281.30M, free cash flow $50.69M.
Why three lenses on FMC, not one.
A single reasoning model has blind spots it doesn’t know about. We examine FMCacross Quality (fundamentals), Momentum (price action and sentiment), and Context (macro/sector). Disagreement between lenses is surfaced, not hidden — it’s how you know when HOLD is the honest call.
Read the full methodologyDrop it in your newsletter or blog.
Free to embed. Updates every 6 hours. Links back to the full brief.
<iframe src="https://clearpathinvest.app/embed/FMC" width="100%" height="420" frameborder="0" loading="lazy" title="ClearPath FMC brief"></iframe>